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Abstract
Background: Peutz-Jeghers syndrome (PJS) is characterized by intestinal polyposis, mucocutaneous pigmentation and an
increased cancer risk, usually caused by mutations of the STK11 gene. This study collected epidemiological, clinical and
genetic data from all Uruguayan PJS patients.
Methods: Clinical data were obtained from public and private medical centers and updated annually. Sequencing of the
STK11 gene in one member of each family was performed.
Results and discussion: 25 cases in 11 unrelated families were registered (15 males, 10 females). The average age of
diagnosis and death was 18 and 41 years respectively. All patients had characteristic PJS pigmentation and gastrointestinal
polyps. 72% required urgent surgery due to intestinal obstruction. 3 families had multiple cases of seizure disorder,
representing 20% of cases. 28% developed cancer and two patients had more than one cancer. An STK11 mutation was
found in 8 of the 9 families analyzed. A unique M136K missense mutation was noted in one family. Comparing annual live
births and PJS birth records from 1970 to 2009 yielded an incidence of 1 in 155,000.
Conclusion: The Uruguayan Registry for Peutz-Jeghers patients showed a high chance of emergent surgery, epilepsy,
cancer and shortened life expectancy. The M136K missense mutation is a newly reported STK 11 mutation.
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Introduction
Peutz-Jeghers syndrome (PJS) is a rare hereditary disorder
characterized by intestinal polyposis, mucocutaneous pigmenta-
tion and increased risk for cancer. The sine qua non of the diagnosis
of Peutz-Jeghers syndrome (PJS) is the hamartomatous gastroin-
testinal polyp characterized histopathologically by the unique
finding of mucosa with interdigitating smooth muscle bundles in a
characteristic branching tree appearance [1]. Cutaneous hyper-
pigmented macules are rarely present at birth; they become
pronounced in most individuals before the fifth year, but then may
fade in puberty and adulthood. Histologically, increased melano-
cytes are observed at the epidermal-dermal junction, with
increased melanin in the basal cells. A 93% cumulative lifetime
risk of cancer was observed in a large collected series from PJS
registries [2] but another series reported a risk for noncutaneous
malignancy of 53% [3]. Linkage studies mapped the genetic basis
for disease to 19p13.3 [4] and germ line mutations in the serine
threonine kinase 11 (STK11) gene have been identified as the
major cause of PJS [5]. However, linkage studies suggest that a
minority of families with PJS do not have STK11 mutations [6].
Uruguay is a South American country with 3 million habitants,
mostly of European origin. The first PJS patient in Uruguay was
reported in 1968 [7]. The aim of this study was to collect and
analyze epidemiological, clinical and genetic data from all patients
with PJS in Uruguay.
Materials And Methods
All known PJS patients in Uruguay have been included in a
National Registry since December 2000. Information about PJS
patients was obtained from public and private medical centers or
submitted by treating physicians. Patients were contacted person-
ally or through their treating clinicians. Clinical data were input
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into a digital chart and updated annually. Data was collected from
a standardized formal questionnaire developed for this study and a
review of clinical records retrospectively [8].
The diagnosis of PJS was made according to defined criteria,
which include the observation of typical mucocutaneous pigmen-
tation and/or the presence of 2 or more pathognomonic
hamartomatous gastrointestinal polyps. In first-degree relatives of
clinically diagnosed PJS individuals, observation of mucocutane-
ous pigmentation was sufficient for diagnosis. This diagnostic
criteria follows the working definition of PJS suggested by
Giardiello et al. [9] and further refined in a recent consensus
meeting [10]. Figure 1 shows representative cutaneous pigmenta-
tion in one of our patients. This individual has seen the manuscript
and figure and has provided his written informed consent for
publication. Endoscopies and polypectomies were done as a result
of surveillance in patients with a known family history of PJS or
the result of diagnostic colonoscopy due to symptoms.
In a single individual, a clinical diagnosis of PJS may be made
when any one of the following is present:
N Two or more histologically confirmed PJ polyps.
N Any number of PJ polyps detected in one individual who has a
family history of PJS in close relative (s).
N Characteristic mucocutaneous pigmentation in an individual
who has a family history of PJS in close relative (s).
N Any number of PJ polyps in an individual who also has
characteristic mucocutaneous pigmentation.
A calculation of PJS incidence was performed using live birth
records from 1915 to 2009 with the recorded birth of each case of
PJS. The incidence of PJS was also calculated for births before and
after 1970.
The study protocol and consent were approved by the ethics
committee of the National Medical School at Montevideo,
Uruguay and written informed consent was obtained from all
patients who underwent genetic analysis. Information on medical
history and family medical history was obtained by a standardized
6 page questionnaire. Informed and written consent was obtained
from the next of kin on the behalf of 3 minors who participated in
the study. The ages of the minors were 12, 14, and 16 years of age.
Peripheral blood samples were collected from one affected
member of each available family. Personal details were noted in a
questionnaire at the time of blood sample collection. Samples were
stripped of individual identifiers and relabeled with a unique
random identifying number for subsequent transmission to the
laboratory. DNA was extracted from the submitted samples using
standard procedures. The genetic analysis was performed in a
CLIA-certified laboratory (GeneDx, Gaithersburg, Maryland).
Sequencing of the STK11 gene was performed to investigate the
presence of gene mutation. Exons 1–9 of the STK11 gene were
PCR-amplified from genomic DNA obtained from the submitted
specimen. Bi-directional sequence was obtained and DNA
sequence was analyzed and compared to the published gene.
Array-based comparative genomic hybridization (aCGH) using a
custom designed oligonucleotide array (ExonArrayDx v.1.0) was
also performed. The array contains DNA oligonucleotide probes
that cover all exons and introns of the STK11 gene. Hybridization
data were analyzed with Agilent Technologies software (DNA
Analytics) to evaluate copy number at the exon level. The
ExonArray is designed to detect most single-exon deletions and
duplications. Probe sequences and locations are from the human
genome build 18. Positive results were confirmed by quantitative
PCR of the STK11 gene. Confirmation of the presence of
observed sequence variant (s) was achieved by re-sequencing the
identified specific region of the gene using another aliquot of the
prepared DNA, to confirm its presence. This was done by either
sequence analysis of the specific exon, designed a restriction
analyses, or used a quantitative PCR analysis such as MLPA.
Results
Clinical Presentation
Twenty-five cases in eleven unrelated families were registered
including 15 males and 10 females (Table 1). The age range of
participants was between 12 and 65 years of age. Of the index
cases, 5 of the 11 families had family history of PJS; in 4 there was
no evidence of family history and in 2 the family history was
unknown prior to the initiation of this study. The average age at
time of diagnosis was 18.3 years (63.1; minimum = 2, maximum
= 65). Age at diagnoses differed between sexes, but not signifi-
cantly (14.662.5 for males and 23.866.8 for females, p = 0.156).
The male to female ratio was 1:0.67.
All 25 patients had characteristic PJS pigmentation and from
those who had evaluation (either by endoscopy, radiology, capsule
endoscopy or surgery) of the gastrointestinal tract all had polyps
(n = 22). In 3 cases no evaluation of the gastrointestinal tract was
performed but these individuals had classical pigmentation and
were first degree relatives of other members with both pigmen-
tation and polyposis.
The 3 cases whose GI tracts were not evaluated belong to the
same family. Of 16 cases that had a small bowel evaluation all
had polyposis. Colon polyps were present in 17 of 19 patients
that received evaluation of the colon by colonoscopy. Families 2,
5, and 10 were comprised of a single individual. Genetic testing
was not performed in families 2 and 5 and did not show a
deletion in family 10. All 3 individuals had characteristic PJS
pigmentation and gastrointestinal hamartomas. In families 2 and
10 the hamartomas were diagnosed by the same university
hospital pathologist who specializes in gastrointestinal pathology
and polyps in family 5 was confirmed by an experienced
pathologist at a public hospital. No central pathology reviewed
occurred.
In Case 1 (Table 1) a colonic hamartomatous polyp with
adenomatous changes and high grade dysplasia was resected at
18 years of age and no recurrence has been seen in 10 years of
follow up.
Figure 1. Characteristic peri-oral melanotic pigmentation more
pronounced on the lower lip.
doi:10.1371/journal.pone.0079639.g001
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Intussusception, a serious mechanical complication, was noted
in eighteen cases (72%). These cases required urgent surgery for
small bowel obstruction secondary to the presence of polyps.
Eleven cases required more than one surgery (median 2;
minimum = 2, maximum = 4). In contrast to other series of
PJS patients [11], no intussusceptions of the stomach or colon
were noted.
Eleven cases (44%) had iron-deficiency anemia, including 40%
of 15 males and 50% of 10 affected females.
Five individuals (20%) in 3 separate families had a seizure
disorder confirmed by a neurologist. An epidemiological study in
Uruguay reports a prevalence of epilepsy of 1.15%. The difference
in reported epilepsy in PJS patients compared with the national
average is significant (p,0.0001). [12].
Seven patients (28%) developed cancer and two patients had
more than one cancer, with breast (N = 4) being the most frequent
site. The others sites were small bowel (1), thyroid (2), rectum (1),
lung (1) and kidney (1). The average age at first cancer was
43 years (range 33–54).
Other findings found in this group of patients were: testicular
calcifications in one case and in another case, low grade
fibrosarcoma of the leg that required surgical excision.
Average age for all-causes of death was 41 years. Cancer was
the most frequent cause. The causes of death were: cancer (n = 5),
postoperative complications after urgent surgery due to polyposis
(n = 1), meningitis (n = 1) and car accident (n = 1). If the patient that
died in the car accident is not included, the average age of death
would be 44 years. For cancer patients the average age for death
was 49 years (range 44–54). The median time to cancer diagnosis
calculated using Kaplan-Meier techniques was 45 years of age and
the median time to death was 49 years of age.
Incidence of PJS in Uruguay
In all, we observed 25 cases of PJS born since 1915 versus
4.7 million live births in Uruguay, 1915–2009, an incidence of 1 in
190,000 live births. This does not account for deaths before
entering the registry. Restricting to the period from 1970 to
present (14 cases of PJS), during which period minimal loss due to
death is expected, yielded an incidence of 6.5 per million births or
about 1 in 155,000 live births.
STK11 Mutation Analysis
A mutation in the STK11 gene was found in 8 of the 9
families analyzed (Table 1). Deletion of all or part of the STK11
gene was identified in 5 patients from 5 families. Targeted array
CGH showed that Family 1 had a complete deletion of STK11
while Families 4, 7 and 8 showed deletion of exon 1 and Family
3 had deletion of exons 2 and 3 (results from Multiplex Ligation
Probe Amplification is shown in fig. 2). Missense mutations were
found in 3 families who did not have deletions. Case 22 was
heterozygous for a T.A nucleotide substitution in exon 3,
resulting in the replacement of a Methionine codon (ATG) with
a Lysine codon (AAG) at amino acid position 136. The sequence
data and chromatographs for the mutation M136K (Family 9)
are shown on Fig. 3. A schematic detailing the structure of the
STK 11 gene and the location of the novel mutation is shown in
figure 4. Family 9 had 12 affected family members, 3 of whom
suffered from epilepsy (Table 1). Family 8 is heterozygous for an
A.G nucleotide substitution at the +1 position of intron 2 of the
STK11 gene. Case 9 showed deletion of a Cytosine at position
666 (CGCC{C}GAGA) which results in a frameshift mutation p.
Glu223ArgfsX64. Case 24 did not show any detectable
mutations either by targeted array CGH or by capillary
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pigmentation and confirmed gastrointestinal hamartomatous
polyps. She had a history of three different primary cancers
(breast, thyroid, kidney) but no family history of PJS.
Discussion
Peutz-Jeghers syndrome is a rare genetic disorder with an
estimated incidence of 1 in 120,000 live births [13]. The lack of
national PJS registries makes the estimation of PJS incidence
imprecise. Our study of annual and PJS birth rates estimated an
incidence of 1/155,000 live births since 1970 and 1/190,000 since
1915, which is in agreement with other reported figures. In this
study, we report data from the Uruguayan Registry for PJS
patients, focusing on clinical and genetics findings. Uruguay is a
country with 3 million habitants, with few tertiary centers. These
characteristics allow us to contact each center and to hypothesize
that all PJS patients in the country were reached by our registry.
We cannot exclude the possibility that some individuals in remote
areas of the country may have been missed. In other PJS series the
diagnosis of PJS has been made in individuals who lack
characteristic mucocutaneous pigmentation. In our series 100%
of PJS patients had characteristic pigmentation. Therefore our
calculation of incidence may be an underestimation of the
prevalence of PJS. Currently, there are 17 individuals with PJS
alive and being followed actively. For 16 of these individuals
annual follow up has been completed, so that we have data of the
ages of onset and phenotypes associated with PJS. Another
weakness of our study is that there was no central pathology review
conducted.
In familial cases, PJS is inherited in an autosomal dominant
manner. The male to female ratio in our study was 1:0.67, which is
similar to the ratio reported in Familial Polyposis Coli (1:0.61)
[10]. About 50% of probands have an affected parent and about
50% have no family history of PJS [14]. In a Korean series of PJS
patients, Choi et al. reported a family history in 47%, no family
history in 50% and unknown in 3% [15]. In the current study,
46% of index cases had a positive family history.
Melanotic pigmented macules varying from 1 to 5 mm in size
may be found on the vermilion border of the lips, labial mucosa,
palate, and tongue [16]. The lips are the most frequent location
accounting for the 94.1% of a large series from Japan [10]. In our
series, 100% of cases presented with pigmentation of the inferior
lip. Hamartomatous gastrointestinal polyps are the hallmark of this
syndrome. PJS hamartomatous polyps are characterized histo-
pathologically by the unique finding of mucosa with interdigitating
smooth muscle bundles in a characteristic branching tree
appearance. These polyps are most prevalent in the small intestine
[17], as we described in our patients. In a large series of 182 cases
reported from the Mayo Clinic, 96% of patients had small bowel
polyps, 60% had colorectal polyps and 24% stomach polyps [18].
Individuals with PJS are at increased risk for intestinal and
extraintestinal malignancies. Boardman et al. [3] found that
individuals with PJS had a 9.9-fold increased relative risk for
cancer; relative risks (RR) were highest for gastrointestinal cancer
(RR = 151) and breast cancer (RR = 20.3). Choi et al. [15]
reported a mean age at cancer diagnosis in probands of 36 years.
In our series the median age at first cancer was later but still young
for cancer (43 years) and similar to a recent Dutch study [19],
which found the median age at cancer onset to be 45 years of age.
The risk for pancreatic cancer is greatly increased over the
population risk [8], but there were no reports of pancreatic cancer
in our series. Lim et al. [20] reported that 8% and 32% of women
Figure 2. MLPA data shows small intragenic deletion in STK11 gene for patient # 3.
doi:10.1371/journal.pone.0079639.g002
Uruguayan PJS Registry
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with PJS developed breast cancer by age 40 years and 60 years,
respectively. In Lim’s study all patients were mutation positive.
Thus far we have found 2 patients from 2 families that presented
with breast cancer at 36 and 65 years old. The youngest died from
metastatic breast cancer 8 years after the diagnosis.
In a recent retrospective review from Mayo Clinic, the overall
survival of PJS patients was significantly shorter than the expected
survival of an age-and gender-matched reference population with
a median age of death of 51 years [21]. In a Japanese series
comprising 222 PJS patients, 43% of deaths before age 30 were
secondary to GI polyps, whereas 60% of deaths over the age of
30 years were due to malignancy [11]. Within our patients, cancer
was the most frequent cause of death and the average age for all-
causes of death was 41 years. A low grade fibrosarcoma was also
Figure 3. Sequence data and chromatographs for the mutation M136K from patient # 22.
doi:10.1371/journal.pone.0079639.g003
Figure 4. A schematic of the structure of STK11 and novel M136K mutation detected in family 9, patient 22.
doi:10.1371/journal.pone.0079639.g004
Uruguayan PJS Registry
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reported in our series. Fibrosarcoma has not previously been
reported as a clinical feature of PJS, however, STK11 interacts
with TP53 in regulation of apoptosis, and dysregulation of STK11
may have some impact on sarcoma risk, as is noted in patients with
inherited p53 mutations.
As other polyposis syndromes, PJS may develop extra-intestinal
findings. In our series we found testicular calcifications in one
patient. Males with PJS are at risk for development of testicular
tumors referred to as large cell calcifying sertoli cell tumors [22].
Gastrointestinal bleeding and bowel obstruction are common non-
malignant complications of PJS. In our series 72% of 25 patients
suffered intussusceptions requiring emergency surgery. Our
experience is quite similar to a recently reported Dutch series
where 69% of 110 PJS experienced intussusceptions [23]. Anemia
was a frequent finding as in other PJS series. Tan et al. [24]
reported a prevalence of 42% of patients with anemia (similar to
42% in our population). Anemia is generally related to bleeding
from GI polyps and the patients may present with rectal bleeding
or hematemesis [17].
STK11 is a tumor suppressor serine/threonine-protein kinase
[25] that controls the activity of AMP-activated protein kinase
(AMPK) family members, thereby playing a role in various
processes such as cell metabolism and the vascular endothelial
growth factor signaling pathway [26], cell polarity [27], p-53
dependent apoptosis [28] and DNA damage response. STK11 acts
by phosphorylating the T-loop of AMPK family proteins, leading
to activation of PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1,
MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2,
SIK3 and SNRK but not MELK. STK11 acts as a key upstream
regulator of AMPK by mediating phosphorylation and activation
of AMPK catalytic subunits PRKAA1 and PRKAA2: it thereby
regulates inhibition of signaling pathways that promote cell growth
and proliferation when energy levels are low, glucose homeostasis
in liver, activation of autophagy when cells undergo nutrient
deprivation, and B-cell differentiation in the germinal center in
response to DNA damage. STK11 also phosphorylates non-
AMPK family proteins such as STRADA and possibly p53/TP53
and acts as a regulator of cellular polarity by remodeling the actin
cytoskeleton. STK11 is required for cortical neuronal polarization
by mediating phosphorylation and activation of BRSK1 and
BRSK2, leading to axon initiation and specification. STK11 is
also involved in DNA damage response: it interacts with p53/
TP53 and is recruited to the CDKN1A/WAF1 promoter to
participate in transcriptional activation. STK11 is able to
phosphorylate p53/TP53.
The relevance of such result in vivo is however unclear and
phosphorylation may be indirect and mediated by downstream
STK11/LKB1 kinase NUAK1 STK1 may also act as a mediator
of p53/TP53-dependent apoptosis via interaction with p53/TP53:
it translocates to mitochondrion during apoptosis and regulates
p53/TP53-dependent apoptosis pathways.
The diverse clinical findings in patients with Peutz-Jeghers
syndrome reflects the range of cellular activities that it controls.
The most common presenting characteristic of Peutz-Jeghers
syndrome relates to the development of hamartomatous polyps. In
animal models, haploinsufficiency was found to be sufficient for
the development of these polyps. Exact mechanisms that underlie
the development of the hamartomas remains unknown, but may
relate to overgrowth due to loss in activity for autophagy, or
perhaps due to defects in cell polarity, which might cause prolapse
of the colonic crypts [29].
The activity of STK11 in neuronal polarization raises the
possibility that individuals with STK11 mutations may manifest
neurological findings. In addition, individuals with mutations in
TSC1, TSC2, and PTEN, all of which influence cAMP activity
and the MTOR pathway all display neurological findings and an
increased prevalence of epilepsy. In recent papers from Thailand,
Korea, Colombia, Hungary and India, epilepsy was not investi-
gated. Moreover a recent systematic review did not mention this
clinical association. Despite a lack of previous reporting, 5 of our
patients in 3 unrelated families presented with epilepsy (lifetime
prevalence of 19%) including 3 of 12 affected family members with
the novel M136K missense mutation. Epilepsy was reported in
Uruguay by Liard et al. as an association of PJS in 1976 [30] in
this family. In a PJS US registry managed by of one of the authors
(CA) [8], epilepsy was noted with increased frequency (CA,
personal communication). These figures need to be assessed in
other series in order to understand its true significance.
Salloch et al. [31] found that persons with truncating mutations
had more surgical gastrointestinal surgeries, a higher polyp count,
and an earlier age at first polypectomy than persons with non-
truncating mutations. In our study, patients 1,3,4,6,7,8 and 9 had
truncating mutation. These patients had a median of 1.8 surgeries
due to intussusception in contrast to the positive patients with no
truncating mutation that had a median of 1 surgery.
A mutation in the STK11 gene was found in 8 of the 9
Uruguayan families analyzed. Deletion of all or part of the STK11
gene was identified in 5 patients from 5 families. We identified a
novel mutation, M136K which represents a replacement of a
neutral, hydrophobic residue by a charged hydrophilic residue in
the serine/threonine protein kinase 11. M136K is likely to
destabilize a part of the kinase domain. The part it destabilizes
is close to the ATP binding pocket. This may cause the kinase to
be less stable, and become more easily degraded, leading to less
active molecules. As a result AMPK kinase activation, ATP
binding, and hence enzymatic activity by STK11 might be
compromised. If so, M136K might act like the G135R mutant,
which has been reported as a frequent mutation in melanoma
[32], which also compromises control of AMPK. It is also expected
that this non-conservative change would impact either protein-
protein interactions or the secondary structure of the mutant
protein.
In a study of 56 individuals with a clinical diagnosis of PJS in
which a combination of sequence analysis to detect point
mutations and multiple ligand-dependent probe assay (MLPA) to
detect large STK11 deletions was used, STK11 mutation
detection rate was 94% [33]. However, the prevalence of germline
mutation of the STK11 has been reported with very different
frequencies, ranging from 100% [34–35] to only10% [36]. STK11
point mutations account for the large majority of PJS cases
whereas large deletions account for up to 30% of the cases [37].
STK11 mutations can be found in familial PJS and in some
sporadic cases as well [38].
In summary, the analysis of the Uruguayan Registry for Peutz-
Jeghers patients showed a high chance of emergent surgery by
intestinal obstruction, high prevalence of epilepsy, high risk of
cancer and shortened life expectancy. An incidence of 1 in
155,000 live births was recorded in Uruguay. A mutation in the
STK11 gene was present in the 89% of families analyzed, and a
novel, and previously undescribed mutation, was detected in one.
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